期刊文献+

80例多发性骨髓瘤患者临床及细胞遗传学改变与血清白细胞介素6、肿瘤坏死因子α、血管内皮生长因子水平的相关性 被引量:6

原文传递
导出
摘要 目的分析多发性骨髓瘤(multiple myeloma,MM)患者的实验室特征与细胞遗传学之间的关系,探讨细胞遗传学分析在MM分型、分期及预后中的价值。方法采用酶联免疫吸附法对80例患者的血清白细胞介素6(interleukin-6,IL-6)、肿瘤坏死因子a(tumor necrosis factor alpha,TNF-α)、血管内皮生长因子(vascular endothelial growth factor,VEGF)水平进行检测,同时进行骨髓及细胞遗传学分析。结果在80例患者中发现细胞遗传学异常36例(45.0%),后者具有较高的血清IL-6、TNF-α及VEGF水平,与正常核型的患者相比差异有统计学意义。MM患者IL-6、TNF-α、VEGF的平均水平与正常对照组相比差异有统计学意义。结论伴有遗传学异常的MM患者具有较高的血清IL-6、TNF-α、VEGF水平。MM的细胞遗传学异常对判断临床疗效和预后具有一定的指导作用。
机构地区 常州市
出处 《中华医学遗传学杂志》 CAS CSCD 北大核心 2012年第1期95-97,共3页 Chinese Journal of Medical Genetics
  • 相关文献

参考文献13

  • 1Nguyena AN,Stebbinsa EG, Hensona M, et al. Normalizing the bone marrow mieroenvironment with p38 inhibitor reduces multiple myeloma eell proliferation and adhesion and suppresses osteoelast formation. Exp Cell Res,2006,312 : 1909-1923.
  • 2Calasanz MJ,Cigudosa JC,Odero MD, et al. Cytogenetie analysis of 280 patients with multiple myeloma and related disorders: primary breakpoint and clinical correlations. Genes Chromosomes Cancer, 1997,18:84-93.
  • 3Recommendations of the International Standing Committee on Human Cytogenetie Nomenclature. ISCN ( 2009 ): An International System for Human Cytogenetle Nomenclature (2009). Shaffer LG, Slovak ML, Campbell LJ, eds. Karger, 2009.
  • 4Wu KL, Beverloo B, Lokhorst HM, et al. Abnormalities of chromosome lp/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Br J Haematol, 2007,136 : 615-623.
  • 5Nilsson T,Lenhoff S, Turesson I, et al. Cytogenetic features of multiple myeloma: impact of gender, age, disease phase, culture time,and eytokine stimulation. Eur J Haematol, 2002,68: 345- 353.
  • 6张艳,江滨,黄晓军,师岩,何琦,党辉,邱镜滢,陆道培.多发性骨髓瘤的细胞遗传学研究[J].中国实验血液学杂志,2007,15(1):76-78. 被引量:20
  • 7林娜,李艳,田辉.多发性骨髓瘤预后评价指标研究最新进展[J].中国实验血液学杂志,2009,17(1):255-260. 被引量:9
  • 8Engelhardt M,Mertelsmann R. 160 years of multiple myeloma: progress and challenges. Eur J Cancer, 2006,42 : 1507-1509.
  • 9Gao L, Chen XH, Zhang X, et al. Human umbilical cord blood- derived stromal cell, a new resource of feeder layer to expand human umbilical cord blood CD34+cells invitro. Blood Ceils Mol Dis, 2006,36 : 322-328.
  • 10Schmidt-Wolf IG, Glasmacher A, Hahn-Ast C, et al. Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH : diagnostic and prognostic relevance. Cancer Genet Cytogenet, 2006,167 : 20-25.

二级参考文献33

共引文献27

同被引文献96

  • 1金莉,林玉梅,胡南均,毕林涛.老年多发性骨髓瘤的临床特征及预后因素分析[J].实用老年医学,2013,27(5):377-379. 被引量:1
  • 2朱蓉,侯健.多发性骨髓瘤的诊断与治疗[J].白血病.淋巴瘤,2004,13(4):243-245. 被引量:6
  • 3蒋楠,甘欣锦.中医辨治多发性骨髓瘤的体会[J].甘肃中医,2005,18(1):7-7. 被引量:11
  • 4赵莹,李娟,罗绍凯,黄蓓晖.大剂量促红细胞生成素冲击在治疗多发性骨髓瘤贫血中的应用[J].国际输血及血液学杂志,2007,30(4):305-308. 被引量:3
  • 5陆再英,钟南山.内科学[M].第7版.北京:人民卫生出版社.2008:251.
  • 6Sarkar S,Germeraad WTV,Rouschop KMA,et al.Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells. PloS One . 2013
  • 7Schueler J,Wider D,Klingner K,et al.Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ (null)mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies. PLo S One . 2013
  • 8Balasa B,Yun R,Belmar NA,et al.Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-αpathways. Cancer Immunology Immunotherapy . 2015
  • 9Li R,Qian J,Zhang W,etal.Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma. British Journal of Haematology . 2014
  • 10Bolkun L1,Lemancewicz D,Piszcz J,etal.Relationship between tumour necrosis factor-related apoptosis inducing ligand (TRAIL)and vascular endothelial growth factor in human multiple myeloma patients. Hematological Oncology . 2014

引证文献6

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部